Cargando…

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis

BACKGROUND AND PURPOSE: Effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) in relapsing–remitting multiple sclerosis (MS) is well known, but in secondary–progressive (SP)‐MS it is still controversial. Therefore, AHSCT activity was evaluated in SP‐MS using low‐dose immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mariottini, Alice, Bulgarini, Giovanni, Forci, Benedetta, Innocenti, Chiara, Mealli, Fabrizia, Mattei, Alessandra, Ceccarelli, Chiara, Repice, Anna Maria, Barilaro, Alessandro, Mechi, Claudia, Saccardi, Riccardo, Massacesi, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306891/ https://www.ncbi.nlm.nih.gov/pubmed/35146841 http://dx.doi.org/10.1111/ene.15280

Ejemplares similares

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis
por: Manjaly, Zina-Mary, et al.
Publicado: (2019)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis
por: Magyari, Melinda, et al.
Publicado: (2022)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
por: Wang, C, et al.
Publicado: (2016)

A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
por: Nij Bijvank, Jenny A., et al.
Publicado: (2021)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression
por: Wu, Jing, et al.
Publicado: (2023)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n9429q1nmt9gnsg1gfkf0adkeq